Linear and nonlinear QSAR study of N-hydroxy-2-[(phenylsulfonyl)amino]acetamide derivatives as matrix metalloproteinase inhibitors.

The inhibitory activity (IC50) toward matrix metalloproteinases (MMP-1, MMP-2, MMP-3, MMP-9, and MMP-13) of N-hydroxy-2-[(phenylsulfonyl)amino]acetamide derivatives (HPSAAs) has been successfully modeled using 2D autocorrelation descriptors. The relevant molecular descriptors were selected by linear and nonlinear genetic algorithm (GA) feature selection using multiple linear regression (MLR) and Bayesian-regularized neural network (BRANN) approaches, respectively. The quality of the models was evaluated by means of cross-validation experiments and the best results correspond to nonlinear ones (Q2>0.7 for all models). Despite the high correlation between the studied compound IC50 values, the 2D autocorrelation space brings different descriptors for each MMP inhibition. On the basis of these results, these models contain useful molecular information about the ligand specificity for MMP S'1, S1, and S'2 pockets.

[1]  Bahram Hemmateenejad,et al.  Toward an Optimal Procedure for PC-ANN Model Building: Prediction of the Carcinogenic Activity of a Large Set of Drugs , 2005, J. Chem. Inf. Model..

[2]  A quantitative structure–activity relationship study of hydroxamate matrix metalloproteinase inhibitors derived from funtionalized 4-aminoprolines , 2003 .

[3]  Martin T. Hagan,et al.  Gauss-Newton approximation to Bayesian learning , 1997, Proceedings of International Conference on Neural Networks (ICNN'97).

[4]  David Hartsough,et al.  Toward an Optimal Procedure for Variable Selection and QSAR Model Building , 2001, J. Chem. Inf. Comput. Sci..

[5]  A. H. Drummond,et al.  Recent advances in matrix metalloproteinase inhibitor research , 1996 .

[6]  J. Zupan,et al.  Neural networks: A new method for solving chemical problems or just a passing phase? , 1991 .

[7]  John H. Holland,et al.  Adaptation in Natural and Artificial Systems: An Introductory Analysis with Applications to Biology, Control, and Artificial Intelligence , 1992 .

[8]  N Moitessier,et al.  Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors. , 2001, Journal of medicinal chemistry.

[9]  Maykel Pérez González,et al.  Modeling of farnesyltransferase inhibition by some thiol and non-thiol peptidomimetic inhibitors using genetic neural networks and RDF approaches. , 2006, Bioorganic & medicinal chemistry.

[10]  D. Wilson,et al.  Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. , 1997, Journal of medicinal chemistry.

[11]  Stephen Hanessian,et al.  A comparative docking study and the design of potentially selective MMP inhibitors , 2001, J. Comput. Aided Mol. Des..

[12]  Julio Caballero,et al.  Modeling of Cyclin-Dependent Kinase Inhibition by 1H-Pyrazolo[3, 4-d]Pyrimidine Derivatives Using Artificial Neural Network Ensembles , 2005, J. Chem. Inf. Model..

[13]  M Karplus,et al.  Evolutionary optimization in quantitative structure-activity relationship: an application of genetic neural networks. , 1996, Journal of medicinal chemistry.

[14]  Bahram Hemmateenejad,et al.  Application of ab initio theory to QSAR study of 1,4‐dihydropyridine‐based calcium channel blockers using GA‐MLR and PC‐GA‐ANN procedures , 2004, J. Comput. Chem..

[15]  A. Hopfinger,et al.  Construction of 3D-QSAR Models Using the 4D-QSAR Analysis Formalism , 1997 .

[16]  R. Geary,et al.  The Contiguity Ratio and Statistical Mapping , 1954 .

[17]  S. Hanessian,et al.  Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors. , 1999, Bioorganic & medicinal chemistry letters.

[18]  Julio Caballero,et al.  Linear and nonlinear modeling of antifungal activity of some heterocyclic ring derivatives using multiple linear regression and Bayesian-regularized neural networks , 2006, Journal of molecular modeling.

[19]  Hugh M. Cartwright,et al.  Applications of artificial intelligence in chemistry , 1993 .

[20]  H. Birkedal‐Hansen.  Proteolytic remodeling of extracellular matrix. , 1995, Current opinion in cell biology.

[21]  S. Gupta,et al.  A quantitative structure-activity relationship study on some series of anthranilic acid-based matrix metalloproteinase inhibitors. , 2005, Bioorganic & medicinal chemistry.

[22]  A Comparative QSAR Study on Carbonic Anhydrase and Matrix Metalloproteinase Inhibition by Sulfonylated Amino Acid Hydroxamates , 2003, Journal of enzyme inhibition and medicinal chemistry.

[23]  B. Barnett,et al.  Crystal structure of the stromelysin catalytic domain at 2.0 A resolution: inhibitor-induced conformational changes. , 1999, Journal of molecular biology.

[24]  P. Moran.  Notes on continuous stochastic phenomena. , 1950, Biometrika.

[25]  A. Henney,et al.  Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. , 2002, Journal of molecular biology.

[26]  Brian E. Mattioni,et al.  Prediction of dihydrofolate reductase inhibition and selectivity using computational neural networks and linear discriminant analysis. , 2003, Journal of molecular graphics & modelling.

[27]  Julio Caballero,et al.  Modeling of activity of cyclic urea HIV-1 protease inhibitors using regularized-artificial neural networks. , 2006, Bioorganic & medicinal chemistry.

[28]  A quantitative structure-activity relationship study on Clostridium histolyticum collagenase inhibitors: roles of electrotopological state indices. , 2003, Bioorganic & medicinal chemistry.

[29]  Didier Villemin,et al.  Structure-musk odour relationship studies of tetralin and indan compounds using neural networks , 1998 .

[30]  H. V. Van Wart,et al.  Understanding the P1' specificity of the matrix metalloproteinases: effect of S1' pocket mutations in matrilysin and stromelysin-1. , 1996, Biochemistry.

[31]  D. Fairlie,et al.  Protease inhibitors: current status and future prospects. , 2000, Journal of medicinal chemistry.

[32]  Bahram Hemmateenejad,et al.  Genetic Algorithm Applied to the Selection of Factors in Principal Component-Artificial Neural Networks: Application to QSAR Study of Calcium Channel Antagonist Activity of 1, 4-Dihydropyridines (Nifedipine Analogous) , 2003, J. Chem. Inf. Comput. Sci..

[33]  Julio Caballero,et al.  2D Autocorrelation modeling of the activity of trihalobenzocycloheptapyridine analogues as farnesyl protein transferase inhibitors , 2005 .

[34]  Douglas M. Hawkins,et al.  The Problem of Overfitting , 2004, J. Chem. Inf. Model..

[35]  F. Burden,et al.  Robust QSAR models using Bayesian regularized neural networks. , 1999, Journal of medicinal chemistry.

[36]  D. Rappolee,et al.  Basement Membrane and Repair of Injury to Peripheral Nerve: Defining a Potential Role for Macrophages, Matrix Metalloproteinases, and Tissue Inhibitor of Metalloproteinases-1 , 1996, The Journal of experimental medicine.

[37]  Gillian Murphy,et al.  Metalloproteinase inhibitors: biological actions and therapeutic opportunities , 2002, Journal of Cell Science.

[38]  Milan Randic,et al.  Orthogonal molecular descriptors , 1991 .

[39]  N. Moitessier,et al.  N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets. , 2001, Journal of medicinal chemistry.

[40]  S P Gupta,et al.  A quantitative structure-activity relationship study on some matrix metalloproteinase and collagenase inhibitors. , 2003, Bioorganic & medicinal chemistry.

[41]  David J. C. MacKay,et al.  Bayesian Interpolation , 1992, Neural Computation.